In a study of patients with advanced melanoma, the prevalence of cutaneous immune–related adverse events (cirAEs) associated with nivolumab/relatlimab combination therapy was 21.5%, with rash ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Nivolumab plus ipilimumab or relatlimab nearly doubled response rates compared to nivolumab alone in head and neck cancer.

OCC terminates 2021 loss mitigation consent order Wells Fargo inches closer to ending decade-old regulatory woes Fifth consent order closed since 2025 beginning March 17 (Reuters) - A top U.S ...

Arsenal have reportedly demanded approximately £67.5million from Real Madrid for Riccardo Calafiori, who they are said to be keeping a close eye on. Arsenal have a wealth of options in the left ...

TL;DR: Mozilla has introduced a new Terms of Use agreement for Firefox users, granting itself a comprehensive license to utilize all information users upload or enter ...

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 ...

Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345] Technology appraisal guidance Nirogacestat ...

The six Ds of energy transformation form the foundation of Malaysia’s sustainable energy future: > Decentralisation: Empowering commercial and industrial entities to generate their own energy ...